Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2021-09-17, Stock:ABBV, The news for the past five days is as follows:
2021-09-10: NEWS1: Downward Pressures and Flat Earnings Outweigh the AbbVie Inc.'s (NYSE:ABBV) Dividend Yield.NEWS2: AbbVie Declares Quarterly Dividend.NEWS3: 3 Stocks to Watch in September.NEWS4: AbbVie to Highlight Its Leadership in Movement Disorders at the International Parkinson and Movement Disorder Society Virtual Congress 2021.
2021-09-13: NEWS1: Regenxbio Stock Catapults To 7-Month High On AbbVie's $1.75 Billion Bet On Gene Therapy.NEWS2: Why Regenxbio Stock Is Way Up Today.NEWS3: Why Regenxbio Shares Are Trading Higher Today.NEWS4: AbbVie Nabs Eye Disease Gene Therapy From Regenxbio for Up to $1.8 Billion.NEWS5: AbbVie, RegenXBio Ink $1.75B Retinal Gene Therapy Collaboration.NEWS6: AbbVie's deal to develop Regenxbio's investigational gene therapy could be worth $1.8 billion.NEWS7: UPDATE 1-AbbVie, Regenxbio enter deal to develop retinal disease therapy.NEWS8: AbbVie and REGENXBIO Announce Eye Care Collaboration.
2021-09-14: NEWS1: AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know.NEWS2: AbbVie Selloff Overdone, Stock Remains Undervalued: BMO.NEWS3: REGENXBIO (RGNX) Stock Up on Collaboration Deal With AbbVie.NEWS4: AbbVie (ABBV) to Co-Develop Regenxbio Eye Disease Gene Therapy.NEWS5: 5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio Deal.NEWS6: REGENXBIO (RGNX) Moves 31.2% Higher: Will This Strength Last?.
2021-09-15: NEWS1: Is AbbVie's 4.9% Dividend Yield Safe?.
2021-09-16: NEWS1: AbbVie Submits Upadacitinib Applications In US, Europe For Ulcerative Colitis.NEWS2: 2 Embarrassingly Cheap Dividend Stocks to Buy.NEWS3: AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis.

Answer: Decrease